Renaissance Technologies LLC Has $4.10 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Renaissance Technologies LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 545,021 shares of the biotechnology company's stock after selling 44,059 shares during the period. Renaissance Technologies LLC owned approximately 0.26% of BioCryst Pharmaceuticals worth $4,099,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC lifted its holdings in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock valued at $36,776,000 after acquiring an additional 127,708 shares during the last quarter. SkyView Investment Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 3,000 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 78.3% during the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company's stock worth $360,000 after buying an additional 20,818 shares in the last quarter. Franklin Resources Inc. grew its position in BioCryst Pharmaceuticals by 177.8% in the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock worth $1,968,000 after buying an additional 168,790 shares during the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at $1,493,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ BCRX traded up $0.18 during trading hours on Friday, hitting $8.40. The company had a trading volume of 2,551,463 shares, compared to its average volume of 2,802,446. The stock has a market capitalization of $1.75 billion, a P/E ratio of -13.75 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50. The firm's 50 day moving average is $7.74 and its 200-day moving average is $7.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period in the prior year, the company earned $0.28 EPS. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.